Company:  AXSOME THERAPEUTICS, INC. (AXSM)
Form Type:  4
Filing Date:  6/12/2019 
CIK:  0001579428 
Address:  200 BROADWAY, 3RD FLOOR 
City, State, Zip:  NEW YORK, New York 10038 
Telephone:  (212) 332-3241 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$24.78  
Change: 
0.53 (2.19%)  
Trade Time: 
Jun 19  
Market Cap: 
$825.31M
Trade AXSM now with 

© 2019  
Description of Business
We are a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system, or CNS, disorders for which there are limited treatment options. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our core CNS portfolio includes four CNS product candidates, AXS­05, AXS-07, AXS-09, and AXS-12, which are being developed for multiple indications. We are conducting a Phase 3 trial with AXS-05 in treatment resistant depression, or TRD, which we refer to as the STRIDE-1 study, a Phase 2/3 trial in agitation associated with Alzheimer's disease, or AD, which we refer to as the ADVANCE-1 study. Additionally, AXS-05 is currently in a Phase 2 trial in smoking cessation and we recently completed a Phase 2 trial in major depressive disorder, or MDD, which we refer to as the ASCEND study.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    REPORTING OWNERS
    SIGNATURES